EMPLICITI (elotuzumab)
ANTINEOPLASTIC-ANTI-SLAMF7 MONOCLONAL ANTIBODY AGENTS · MULTIPLE MYELOMA
BMS PRIMARYCARE
Drug class
Antineoplastic-Anti-SLAMF7 Monoclonal Antibody Agents
Antineoplastic-anti-SLAMF7 monoclonal antibody agents are a specialized class of targeted immunotherapies that selectively bind to signaling lymphocytic activation molecule family member 7 (SLAMF7), a cell-surface glycoprotein highly expressed on myeloma cells and natural killer (NK) cells. Read more about Antineoplastic-Anti-SLAMF7 Monoclonal Antibody Agents
1 drugs in this class 1 manufacturers
Drugs in Antineoplastic-Anti-SLAMF7 Monoclonal Antibody Agents
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic-Anti-SLAMF7 Monoclonal Antibody Agents preselected. Add indication or manufacturer filters there.
Antineoplastic-anti-SLAMF7 monoclonal antibody agents are a specialized class of targeted immunotherapies that selectively bind to signaling lymphocytic activation molecule family member 7 (SLAMF7), a cell-surface glycoprotein highly expressed on myeloma cells and natural killer (NK) cells.
These agents exert a dual therapeutic mechanism by directly activating endogenous NK cells and tagging malignant plasma cells for antibody-dependent cellular cytotoxicity (ADCC) mediated by immune effector cells.
Represented by elotuzumab, this class is primarily utilized in oncology formularies to treat multiple myeloma, typically in combination with immunomodulatory agents and corticosteroids for patients with relapsed or refractory disease.
-
hellopharmacist.com
Antineoplastic-anti-SLAMF7 monoclonal antibody agents are a specialized class of targeted immunotherapies that selectively bind to signaling lymphocytic activation molecule family member 7 (SLAMF7), a cell-surface glycoprotein highly expressed on myeloma cells and natural killer (NK) cells Represented by elotuzumab, this class is primarily utilized in oncology formularies to treat multiple myeloma, typically in combination with immunomodulatory agents and corticosteroids for patients with relaps...
-
nih.gov
Antineoplastic-anti-SLAMF7 monoclonal antibody agents are a specialized class of targeted immunotherapies that selectively bind to signaling lymphocytic activation molecule family member 7 (SLAMF7), a cell-surface glycoprotein highly expressed on myeloma cells and natural killer (NK) cells
-
cancerresearch.org
Antineoplastic-anti-SLAMF7 monoclonal antibody agents are a specialized class of targeted immunotherapies that selectively bind to signaling lymphocytic activation molecule family member 7 (SLAMF7), a cell-surface glycoprotein highly expressed on myeloma cells and natural killer (NK) cells Represented by elotuzumab, this class is primarily utilized in oncology formularies to treat multiple myeloma, typically in combination with immunomodulatory agents and corticosteroids for patients with relaps...
-
nih.gov
These agents exert a dual therapeutic mechanism by directly activating endogenous NK cells and tagging malignant plasma cells for antibody-dependent cellular cytotoxicity (ADCC) mediated by immune effector cells
-
bmj.com
These agents exert a dual therapeutic mechanism by directly activating endogenous NK cells and tagging malignant plasma cells for antibody-dependent cellular cytotoxicity (ADCC) mediated by immune effector cells
-
cigna.com
Represented by elotuzumab, this class is primarily utilized in oncology formularies to treat multiple myeloma, typically in combination with immunomodulatory agents and corticosteroids for patients with relapsed or refractory disease
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.